Tenderwize
Wróć do wyszukiwania

Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 370 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated value or framework maximum means potential volume is unknown.

Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Pharmaceutical discount agreement for Teriparatid
  • Supply of the active substance to German statutory health insurance funds
Pokaż pełne podsumowanie

Open-House procedure by Techniker Krankenkasse and other German health insurers to conclude discount agreements (Rabattverträge) for the active substance Teriparatid. The procedure allows any eligible pharmaceutical entrepreneur to join at any time during the contract period (01.09.2025 to 31.08.2027). No exclusive rights are granted. The notice explicitly states this is not a public procurement subject to EU procurement law; legal disputes fall under social courts. No estimated value, award criteria, or detailed submission documents were provided in the structured data or XML notice.

Ryzyka

No estimated value or framework maximum means potential volume is unknown.

Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) per § 4 Abs. 18 AMG
  • Must have a valid marketing authorization for the medicinal product per § 21 AMG
  • Must have registered seat in Germany, EU, or EEA

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; in open-house, contracts are concluded with all eligible participants.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid

Conclusion of pharmaceutical discount agreements for Teriparatid under § 130a Abs. 8 SGB V via an open-house procedure. No negotiation, uniform terms. Contract duration max 24 months from 01.09.2025 to 31.08.2027.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; in open-house, contracts are concluded with all eligible participants.

Termin

Deadline Aug 30, 2027

Szczegóły zamówienia

Data publikacji
13 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
457552-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3